tiprankstipranks
Trending News
More News >
Ehealth (EHTH)
NASDAQ:EHTH

Ehealth (EHTH) AI Stock Analysis

Compare
1,018 Followers

Top Page

EH

Ehealth

(NASDAQ:EHTH)

Rating:57Neutral
Price Target:
$4.00
▲(2.83%Upside)
Ehealth's overall stock score reflects a mixed outlook. The company's financial performance shows recovery, with improved margins and revenue growth, but negative cash flows and equity concerns remain. Technical analysis indicates bearish momentum, and valuation metrics are weak due to negative profitability. The earnings call was positive, with strong Medicare segment growth and strategic advancements, but regulatory and litigation challenges pose risks. The absence of notable corporate events does not impact the score.
Positive Factors
Cost Efficiency
Investments in more effective brand advertising and maintaining a more tenured agent resulted in a 24% year-over-year decline in acquisition costs.
Financial Performance
Adjusted EBITDA of $12.5 million beat the -$7 million estimate.
Revenue Growth
First-quarter revenue grew 22%, above the 8% estimate.
Negative Factors
Management and Legal Issues
There is near-term uncertainty around management transition and legal issues as the company navigates the seasonally slower second and third quarters.
Operating Cash Flow
The stock remains a wait-and-see due to pending sustainable positive inflection in operating cash flow.
Revenue Outlook
The modest revenue outlook reflects tough comparison for the upcoming AEP if shopping reverts to more normalized levels and regulatory changes limit plan switching for dual eligibles.

Ehealth (EHTH) vs. SPDR S&P 500 ETF (SPY)

Ehealth Business Overview & Revenue Model

Company DescriptioneHealth, Inc. operates a health insurance marketplace that provides consumer engagement, education, and health insurance enrollment solutions in the United States. The company operates in two segments, Medicare; and Individual, Family and Small Business. Its ecommerce platforms organize and present health insurance information in various formats that enable individuals, families, and small businesses to research, analyze, compare, and purchase a range of health insurance plans. The company operates a marketplace that offers consumers a choice of insurance products, such as Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business, and other ancillary health insurance products from health insurance carriers. It markets health insurance plans through its websites, including eHealth.com, eHealthInsurance.com, eHealthMedicare.com, Medicare.com, PlanPrescriber.com, and GoMedigap.com, as well as through a network of marketing partners. The company also licenses its health insurance ecommerce technology that enables health insurance carriers to market and distribute health insurance plans online; and provides online sponsorship and advertising, and lead referral services. eHealth, Inc. was incorporated in 1997 and is headquartered in Santa Clara, California.
How the Company Makes MoneyeHealth makes money primarily through commissions earned from insurance carriers for the plans sold via its platform. When a customer enrolls in a health insurance plan through eHealth, the company receives a commission from the insurance provider. These commissions can be either a one-time payment or recurring payments for the duration that the customer maintains the policy. eHealth's revenue streams also include advertising and sponsorship opportunities on their platform, although the majority of their income is derived from commissions. The company leverages its partnerships with numerous insurance carriers to offer a diverse range of plans, enhancing their appeal to a wide customer base seeking health insurance solutions. eHealth also invests in marketing and customer service to drive enrollment and enhance user experience, contributing to its earnings.

Ehealth Earnings Call Summary

Earnings Call Date:May 07, 2025
(Q1-2025)
|
% Change Since: -16.88%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Neutral
The earnings call conveyed a mix of strong revenue growth and strategic advancements, especially in the Medicare segment, tempered by regulatory challenges and ongoing litigation. Despite these issues, the overall financial performance and strategic initiatives were positive.
Q1-2025 Updates
Positive Updates
Significant Revenue and Profitability Growth
First quarter revenue grew 22% to $113.1 million, with GAAP net income of $2 million and adjusted EBITDA of $12.5 million. Medicare submissions increased by 22% year-over-year.
Improved Medicare Segment Performance
Medicare segment revenue was $103.7 million, a 26% increase. The segment's gross profit rose 62%, driven by enhanced unit economics and lower acquisition costs.
Innovative Technological Advancements
Launched an AI pilot program to enhance telephonic enrollment, receiving positive initial results and customer feedback.
Strong Cash Position and Collections
Ended the quarter with $155.6 million in cash and short-term marketable securities, driven by robust cash collections from Medicare enrollments.
Negative Updates
Litigation Concerns
The Department of Justice filed a complaint naming eHealth, raising concerns about regulatory compliance, although the company intends to challenge the claims.
Challenges with D-SNP Enrollment Rules
Anticipated challenging year-over-year comparisons for Q2 due to regulatory changes in dual special needs plans enrollment rules.
Decline in Employer and Individual Segment
Revenue and gross profit for the Employer and Individual segment decreased, with legacy products in decline despite growth in ancillary and ICHRA opportunities.
Company Guidance
During the first quarter of fiscal year 2025, eHealth Inc. demonstrated significant financial growth and operational success, with revenue reaching $113.1 million, marking a 22% year-over-year increase. The company reported a GAAP net income of $2 million and an adjusted EBITDA of $12.5 million. Medicare submissions surged by 22%, with the agency fulfillment model experiencing a 26% increase. The hybrid enrollment approach, combining online tools and advisory support, saw the strongest growth at 38%. The acquisition cost per approved Medicare member declined by 10%, reflecting enhanced marketing and sales efficiencies. eHealth ended the quarter with $155.6 million in cash and equivalents, highlighting robust collections from Medicare enrollments. Despite ongoing regulatory adjustments, the company maintained a proactive stance on member retention and technological innovations, including a pilot AI integration in its telephonic enrollment process. The company has not altered its 2025 guidance, citing the early stage in the annual cycle and evolving market dynamics.

Ehealth Financial Statement Overview

Summary
Ehealth's financial performance indicates recovery, with improved margins and revenue growth in the TTM period. The balance sheet reflects a stable position with low leverage, though persistent negative cash flows and potential equity erosion pose risks. Key improvements are promising, but cash management and profitability sustainability remain critical.
Income Statement
72
Positive
Ehealth has shown significant improvement in its financial performance, with a notable revenue growth of 27.92% in TTM (Trailing-Twelve-Months) compared to the previous year. The gross profit margin for TTM is 92.91%, showing strong operational efficiency, while the net profit margin has improved to 5.25% from negative figures in prior years. EBIT and EBITDA margins for TTM are 8.38% and 12.35%, respectively, indicating enhanced profitability. However, previous years exhibited significant losses, which still present a risk factor.
Balance Sheet
65
Positive
The debt-to-equity ratio in TTM is 0.16, reflecting a conservative leverage position. Ehealth's equity ratio is 51.15%, indicating a solid equity base relative to its total assets. Return on equity (ROE) has improved to 4.98% from negative figures, pointing towards better utilization of equity. However, the reduction in stockholders' equity over recent years raises concerns about long-term sustainability if this trend continues.
Cash Flow
58
Neutral
Ehealth's cash flow analysis reveals challenges, with operating cash flow remaining negative at -$12.01 million in TTM. The free cash flow growth has improved from -$31.22 million in the previous year to -$22.37 million in TTM. However, the operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income to cash. Although there are signs of improvement, the cash flow situation still poses risks.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue552.57M532.41M452.87M405.36M538.20M582.77M
Gross Profit513.55M530.62M451.10M403.71M536.21M578.69M
EBITDA68.23M46.81M-9.16M-42.37M-105.18M66.27M
Net Income28.99M10.06M-28.21M-88.72M-104.38M45.45M
Balance Sheet
Total Assets1.14B1.16B1.11B1.11B1.15B1.04B
Cash, Cash Equivalents and Short-Term Investments155.59M82.24M121.65M144.40M123.23M93.38M
Total Debt95.34M96.92M103.16M106.80M41.37M46.56M
Total Liabilities207.55M567.00M209.26M198.37M167.18M202.46M
Stockholders Equity581.62M588.43M904.08M914.24M982.11M837.56M
Cash Flow
Free Cash Flow-22.37M-31.22M-17.47M-42.38M-183.48M-131.62M
Operating Cash Flow-12.01M-18.37M-6.69M-26.87M-162.62M-107.86M
Investing Cash Flow-32.66M-48.42M-15.89M25.86M-12.63M-73.28M
Financing Cash Flow-9.11M-9.67M-6.22M63.84M213.24M201.25M

Ehealth Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.89
Price Trends
50DMA
4.46
Negative
100DMA
5.93
Negative
200DMA
6.35
Negative
Market Momentum
MACD
-0.11
Negative
RSI
37.03
Neutral
STOCH
14.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EHTH, the sentiment is Negative. The current price of 3.89 is below the 20-day moving average (MA) of 4.16, below the 50-day MA of 4.46, and below the 200-day MA of 6.35, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 37.03 is Neutral, neither overbought nor oversold. The STOCH value of 14.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EHTH.

Ehealth Risk Analysis

Ehealth disclosed 43 risk factors in its most recent earnings report. Ehealth reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ehealth Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
C$14.74B6.3922.27%5.55%29.68%-22.81%
60
Neutral
$417.99M0.82%20.41%93.09%
57
Neutral
$125.55M3.19%17.04%74.07%
51
Neutral
$5.27M-238.61%2.40%94.65%
51
Neutral
$22.90M11.44-3.92%0.48%-127.19%
46
Neutral
$66.80M0.80%13.18%97.01%
45
Neutral
$12.26M-12.03%158.74%14.86%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
EHTH
Ehealth
3.89
-0.59
-13.17%
RELI
Reliance Global Group
1.50
-2.62
-63.59%
HUIZ
Huize Holding
2.41
-2.59
-51.80%
TIRX
Tian Ruixiang Holdings
1.21
-0.83
-40.69%
SLQT
SelectQuote
2.37
-1.18
-33.24%
GOCO
GoHealth
5.93
-5.82
-49.53%

Ehealth Corporate Events

Executive/Board ChangesShareholder Meetings
eHealth Extends CEO Tenure Amid Leadership Transition
Neutral
Jun 24, 2025

On June 18, 2025, eHealth, Inc. announced that its CEO, Fran Soistman, will continue to serve until a successor is appointed, with a transition period extending to December 31, 2025. To ensure leadership stability during this period, Soistman will receive a retention cash award and a performance-based bonus, contingent on his continued service. Additionally, at the 2025 Annual Meeting of Stockholders, eHealth’s shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the maximum number of shares by 1,500,000, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025.

The most recent analyst rating on (EHTH) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Ehealth stock, see the EHTH Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 12, 2025